Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $233,999.96 in Stock

Posted by Geri Gentry on Aug 29th, 2026

SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 11,636 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $20.11, for a total value of $233,999.96. Following the completion of the transaction, the insider owned 223,284 shares of the company’s stock, valued at $4,490,241.24. This trade represents a 4.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total value of $112,353.85.
On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25.
On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The shares were sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Stock Performance

Shares of SIBN opened at $19.21 on Friday. The company has a 50-day moving average of $17.87 and a two-hundred day moving average of $15.45. The stock has a market cap of $851.96 million, a price-to-earnings ratio of -56.50 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, equities research analysts expect that SiBone will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

SIBN has been the topic of a number of research analyst reports. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. TD Cowen lifted their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Truist Financial reiterated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Finally, UBS Group increased their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.17.

View Our Latest Analysis on SIBN

Hedge Funds Weigh In On SiBone

A number of hedge funds have recently added to or reduced their stakes in SIBN. Royal Bank of Canada raised its position in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares in the last quarter. Versant Capital Management Inc grew its position in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after acquiring an additional 887 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after purchasing an additional 1,459 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.